Update on ABT199 in CLL
Description: Speaking to the European Medical Journal from the 19th Congress of the European Haematology Association (EHA) meeting, Prof. John Seymour from Sir Peter MacCallum, Department of Oncology, Australia, outlines the three presentations at the meeting updating clinicians on the latest findings with ABT199 , an investigational B-cell lymphoma 2 (BCL-2) selective inhibitor.
Firstly, he outlines the results from the monotherapy dose-escalation study, which has completed recruitment (n=105) and shown positive clinical findings. Secondly , he summarises the findings from the step-wise programme developed to avoid tumour lysis syndrome with ABT199. Thirdly , Prof. Seymour discusses the promising early data from the ABT199 plus rituximab combination study, including the early signals for minimal residual disease (MRD).
Shared By : patientpower
Posted on : 07/15/14
Added : 4 years ago